"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

Assessing patient fitness involves more than evaluating chronological age, noted Brandon Blue, MD, of the Moffitt Cancer ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

Brian Griffin has incurable blood cancer and, while he is well enough at the moment after a second and final stem cell ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be ...

It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by ...

These six high-yield dividend stocks are universally loved by investment professionals and they now offer reasonable entry ...

Redburn Atlantic upgraded shares of Autolus Therapeutics (NASDAQ:AUTL – Free Report) from a neutral rating to a buy rating in ...

( MENAFN - GlobeNewsWire - Nasdaq) Stem Cell Therapy market Size Was Valued at USD 12.05 Billion in 2023, and is Projected to Reach USD 31.33 Billion by 2032, Growing at a CAGR of 11.20% From ...

Keymed Biosciences has licensed global rights for CM336, excluding Greater China, to Platina Medicines in a deal worth up to ...

Rising incidence of cancer around the world is projected to primarily augment the demand for CAR T-cell therapy (CAR-T (Chimeric Antigen Receptor T-cell) therapy) over the coming years.Westford, USA, ...

Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...